Macugen causes worrying IOP spikes

Article

Pegaptanib sodium (Macugen) injections can result in a significant transient rise in intraocular pressure (IOP), which may be damaging to the optic nerve, particularly in patients with advanced glaucoma.

Pegaptanib sodium (Macugen) injections can result in a significant transient rise in intraocular pressure (IOP), which may be damaging to the optic nerve, particularly in patients with advanced glaucoma, according to a study published in the June issue of the American Journal of Ophthalmology.

Ronald Frenkel from the Eye Research Institute and colleagues from the East Florida Eye Institute, Florida, USA conducted a review of 75 eyes treated with intravitreal injections of pegaptanib (0.09 ml).

The mean pre-injection IOP was 14±3 mmHg. At one minute post-injection, mean IOP was 38±14 mmHg, at three to 10 minutes it was 34±9 mmHg and at 11 to 20 minutes it was 26±10 mmHg. Most patients' IOP diminished significantly 30 minutes after the injection.

The authors concluded that this dramatic rise in IOP following injections of pegaptanib could cause damage to the optic nerve, particularly in patients with advanced glaucoma and hence its use in glaucomatous patients should be approached with caution.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.